• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝病异质性的见解

Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity.

作者信息

Arrese Marco, Arab Juan P, Barrera Francisco, Kaufmann Benedikt, Valenti Luca, Feldstein Ariel E

机构信息

Department of Gastroenterology, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

Centro de Envejecimiento y Regeneración (CARE), Departamento de Biología Celular y Molecular, Facultad de Ciencias Biologicas, Pontificia Universidad Catolica de Chile, Santiago, Chile.

出版信息

Semin Liver Dis. 2021 Nov;41(4):421-434. doi: 10.1055/s-0041-1730927. Epub 2021 Jul 7.

DOI:10.1055/s-0041-1730927
PMID:34233370
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8492194/
Abstract

The acronym nonalcoholic fatty-liver disease (NAFLD) groups a heterogeneous patient population. Although in many patients the primary driver is metabolic dysfunction, a complex and dynamic interaction of different factors (i.e., sex, presence of one or more genetic variants, coexistence of different comorbidities, diverse microbiota composition, and various degrees of alcohol consumption among others) takes place to determine disease subphenotypes with distinct natural history and prognosis and, eventually, different response to therapy. This review aims to address this topic through the analysis of existing data on the differential contribution of known factors to the pathogenesis and clinical expression of NAFLD, thus determining the different clinical subphenotypes observed in practice. To improve our understanding of NAFLD heterogeneity and the dominant drivers of disease in patient subgroups would predictably impact on the development of more precision-targeted therapies for NAFLD.

摘要

非酒精性脂肪性肝病(NAFLD)这一缩写涵盖了一群异质性患者。尽管在许多患者中,主要驱动因素是代谢功能障碍,但不同因素(即性别、一种或多种基因变异的存在、不同合并症的共存、多样的微生物群组成以及不同程度的酒精摄入等)之间存在复杂而动态的相互作用,从而决定了具有不同自然史和预后的疾病亚表型,并最终导致对治疗的不同反应。本综述旨在通过分析现有数据,探讨已知因素对NAFLD发病机制和临床表型的不同贡献,从而确定在实践中观察到的不同临床亚表型。增进我们对NAFLD异质性以及患者亚组中疾病主要驱动因素的理解,有望对开发更精准靶向的NAFLD治疗方法产生影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05ce/8492194/4f2f5c165bf6/10-1055-s-0041-1730927-i2100020-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05ce/8492194/cc8a9e596bf7/10-1055-s-0041-1730927-i2100020-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05ce/8492194/4f2f5c165bf6/10-1055-s-0041-1730927-i2100020-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05ce/8492194/cc8a9e596bf7/10-1055-s-0041-1730927-i2100020-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05ce/8492194/4f2f5c165bf6/10-1055-s-0041-1730927-i2100020-2.jpg

相似文献

1
Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity.非酒精性脂肪性肝病异质性的见解
Semin Liver Dis. 2021 Nov;41(4):421-434. doi: 10.1055/s-0041-1730927. Epub 2021 Jul 7.
2
Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management.精准医学方法在非酒精性脂肪性肝病诊断和管理中的应用展望。
Adv Ther. 2021 May;38(5):2130-2158. doi: 10.1007/s12325-021-01690-1. Epub 2021 Apr 7.
3
Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name.非酒精性脂肪性肝病与代谢相关脂肪性肝病:名称改变的流行率、结局及意义。
Clin Mol Hepatol. 2022 Oct;28(4):790-801. doi: 10.3350/cmh.2022.0070. Epub 2022 May 11.
4
ADH1B∗2 Is Associated With Reduced Severity of Nonalcoholic Fatty Liver Disease in Adults, Independent of Alcohol Consumption.ADH1B∗2 与非酒精性脂肪性肝病严重程度降低相关,与酒精摄入无关。
Gastroenterology. 2020 Sep;159(3):929-943. doi: 10.1053/j.gastro.2020.05.054. Epub 2020 May 23.
5
Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease.头发中的乙基葡糖苷检测到疑似非酒精性脂肪性肝病患者中有很高的有害饮酒率。
J Hepatol. 2022 Oct;77(4):918-930. doi: 10.1016/j.jhep.2022.04.040. Epub 2022 May 20.
6
Nonalcoholic fatty liver disease and polycystic ovary syndrome.非酒精性脂肪性肝病与多囊卵巢综合征
World J Gastroenterol. 2014 Jul 14;20(26):8351-63. doi: 10.3748/wjg.v20.i26.8351.
7
Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.非酒精性脂肪性肝病的临床流行病学和疾病负担。
World J Gastroenterol. 2017 Dec 21;23(47):8263-8276. doi: 10.3748/wjg.v23.i47.8263.
8
Nonalcoholic fatty liver disease as a multi-systemic disease.非酒精性脂肪性肝病作为一种多系统疾病。
World J Gastroenterol. 2016 Apr 28;22(16):4079-90. doi: 10.3748/wjg.v22.i16.4079.
9
Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease.酒精性肝病与非酒精性脂肪性肝病的临床差异
World J Gastroenterol. 2014 Jul 14;20(26):8393-406. doi: 10.3748/wjg.v20.i26.8393.
10
Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management.非酒精性脂肪性肝病在瘦人群体中的:预后、结局和管理。
World J Gastroenterol. 2020 Nov 14;26(42):6514-6528. doi: 10.3748/wjg.v26.i42.6514.

引用本文的文献

1
Characterization of Extracellular Vesicles Derived From Human Precision-Cut Liver Slices in Metabolic Dysfunction-Associated Steatotic Liver Disease.代谢功能障碍相关脂肪性肝病中源自人精密肝切片的细胞外囊泡的表征
J Extracell Biol. 2025 Apr 30;4(5):e70043. doi: 10.1002/jex2.70043. eCollection 2025 May.
2
MetALD: New Perspectives on an Old Overlooked Disease.线粒体酒精性肝病:一种被长期忽视的古老疾病的新视角
Liver Int. 2025 May;45(5):e70017. doi: 10.1111/liv.70017.
3
Risk of Serious Bacterial and Non-Bacterial Infections in People With MASLD.

本文引用的文献

1
Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management.精准医学方法在非酒精性脂肪性肝病诊断和管理中的应用展望。
Adv Ther. 2021 May;38(5):2130-2158. doi: 10.1007/s12325-021-01690-1. Epub 2021 Apr 7.
2
Non-alcoholic fatty liver disease and psoriasis - is there a shared proinflammatory network?非酒精性脂肪性肝病与银屑病——是否存在共同的促炎网络?
J Dtsch Dermatol Ges. 2021 Apr;19(4):517-528. doi: 10.1111/ddg.14425. Epub 2021 Mar 25.
3
Exercise as Medicine: The Impact of Exercise Training on Nonalcoholic Fatty Liver Disease.
患有代谢功能障碍相关脂肪性肝病(MASLD)的人群发生严重细菌和非细菌感染的风险
Liver Int. 2025 Apr;45(4):e70059. doi: 10.1111/liv.70059.
4
Integrative analysis of bulk and single-cell RNA sequencing data reveals distinct subtypes of MAFLD based on N1-methyladenosine regulator expression.对批量和单细胞RNA测序数据的综合分析揭示了基于N1-甲基腺苷调节因子表达的MAFLD不同亚型。
Liver Res. 2023 Jun 16;7(2):145-155. doi: 10.1016/j.livres.2023.06.001. eCollection 2023 Jun.
5
Design and rationale for a global novel non-invasive screening observational study using genetics and non-invasive methodologies to identify at-risk MASLD participants: The ALIGN study.一项利用遗传学和非侵入性方法识别高危非酒精性脂肪性肝病(MASLD)参与者的全球新型非侵入性筛查观察性研究的设计与原理:ALIGN研究
Contemp Clin Trials Commun. 2025 Jan 20;44:101437. doi: 10.1016/j.conctc.2025.101437. eCollection 2025 Apr.
6
Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease.以微生物群为中心的代谢功能障碍相关脂肪性肝病治疗方法
Clin Mol Hepatol. 2025 Feb;31(Suppl):S94-S111. doi: 10.3350/cmh.2024.0811. Epub 2024 Nov 28.
7
Postbiotics as Antiinflammatory and Immune-Modulating Bioactive Compounds in Metabolic Dysfunction-Associated Steatotic Liver Disease.后生元作为代谢功能障碍相关脂肪性肝病中的抗炎和免疫调节生物活性化合物
Mol Nutr Food Res. 2024 Dec;68(23):e2400754. doi: 10.1002/mnfr.202400754. Epub 2024 Nov 5.
8
Identifying patient subgroups in MASLD and MASH-associated fibrosis: molecular profiles and implications for drug development.鉴定 MASLD 和 MASH 相关纤维化中的患者亚组:分子谱及对药物研发的意义。
Sci Rep. 2024 Oct 7;14(1):23362. doi: 10.1038/s41598-024-74098-w.
9
Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update.代谢功能障碍相关脂肪性肝病的遗传学:最新进展。
Clin Gastroenterol Hepatol. 2024 Nov;22(11):2177-2187.e3. doi: 10.1016/j.cgh.2024.05.052. Epub 2024 Jul 31.
10
MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives.MASH作为肝细胞癌的一种新兴病因:当前认知与未来展望。
Mol Oncol. 2025 Feb;19(2):275-294. doi: 10.1002/1878-0261.13685. Epub 2024 Jun 14.
运动即良药:运动训练对非酒精性脂肪性肝病的影响。
Curr Hepatol Rep. 2020 Dec;19(4):402-411. doi: 10.1007/s11901-020-00543-9. Epub 2020 Sep 9.
4
Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis.钠-葡萄糖协同转运蛋白2抑制剂用于亚洲2型糖尿病患者非酒精性脂肪性肝病的荟萃分析
Front Endocrinol (Lausanne). 2021 Feb 11;11:609135. doi: 10.3389/fendo.2020.609135. eCollection 2020.
5
Therapeutic pipeline in nonalcoholic steatohepatitis.非酒精性脂肪性肝炎的治疗药物研发管线。
Nat Rev Gastroenterol Hepatol. 2021 Jun;18(6):373-392. doi: 10.1038/s41575-020-00408-y. Epub 2021 Feb 10.
6
NIH's 'precision nutrition' bet aims for individualized diets.美国国立卫生研究院的“精准营养”赌注旨在实现个性化饮食。
Science. 2021 Feb 5;371(6529):552. doi: 10.1126/science.371.6529.552.
7
Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?非酒精性脂肪性肝病的白种瘦体型受试者与非瘦体型受试者具有相似的长期预后:是否需要重新评估 BMI 驱动方法?
Gut. 2022 Feb;71(2):382-390. doi: 10.1136/gutjnl-2020-322564. Epub 2021 Feb 4.
8
Experimental models of metabolic and alcoholic fatty liver disease.代谢性和酒精性脂肪性肝病的实验模型
World J Gastroenterol. 2021 Jan 7;27(1):1-18. doi: 10.3748/wjg.v27.i1.1.
9
Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review.非酒精性脂肪性肝病作为人类的一种代谢性疾病:文献综述。
Diabetes Obes Metab. 2021 May;23(5):1069-1083. doi: 10.1111/dom.14322. Epub 2021 Feb 10.
10
Management of non-alcoholic fatty liver disease.非酒精性脂肪性肝病的管理
BMJ. 2021 Jan 18;372:m4747. doi: 10.1136/bmj.m4747.